Harness the proven efficacy of STIVARGA to maximize potential overall survival (OS) for your previously treated patients with mCRC1

In the pivotal CORRECT trial, STIVARGA demonstrated a median OS of 6.4 months vs 5.0 months with placebo for previously treated patients with mCRC1

Significant improvement in OS1,*

Line graph showing OS results from STIVARGA (regorafenib) CORRECT trial and highlighting a 23% reduction in the risk of death.

23% reduction in the risk of
death with STIVARGA1

HR: 0.77
(95% CI, 0.64-0.94) P=0.0102

23% reduction in the risk of
death with STIVARGA1

HR: 0.77
(95% CI, 0.64-0.94) P=0.0102

CORRECT (COloRectal cancer treated with REgorafenib or plaCebo after failure of standard Therapy) was a large, international, placebo-controlled, double-blind, randomized (2:1), phase 3 trial that evaluated the efficacy and safety of STIVARGA in patients with mCRC who had progressed after all approved standard therapies (N=760).1^,2

STIVARGA improved OS in CORRECT, which included patients with historically collected KRAS status (N=729)1
- Historical KRAS status was assessed (59% mutant, 41% KRAS wild-type)
There were 275 deaths out of 505 patients treated with STIVARGA (55%) vs 157 deaths out of 255 patients treated with placebo (62%)1

Interested in additional results that support the STIVARGA clinical experience?

SEE REAL-WORLD DATA FROM STAR-T

Cytotoxic therapy in CORRECT

In CORRECT, patients were able to receive cytotoxic therapy following treatment with STIVARGA2,5

CORRECT trial: 26% of patients received cytotoxic therapy after STIVARGA2^,3

	STIVARGA, n (%)	Placebo, n (%)
Systemic anticancer treatment during CORRECT trial follow-up	(n=505)	(n=255)
Patients with ≥1 medication	131 (26)	76 (30)
Any antineoplastic or immunomodulation agent	130 (26)	74 (29)

Systemic anticancer treatment during CORRECT trial follow-up	STIVARGA, n (%) (n=505)	Placebo, n (%) (n=255)
Patients with ≥1 medication	131 (26)	76 (30)
Any antineoplastic or immunomodulation agent	130 (26)	74 (29)

STIVARGA significantly improved progression-free survival (PFS)

In the pivotal CORRECT trial, STIVARGA demonstrated a 51% reduction in the risk of disease progression or death1^,2

Significant improvement in PFS1^,2,^†

Line graph showing PFS results from STIVARGA (regorafenib) CORRECT trial and highlighting a 51% reduction in the risk of disease progression or death.

51% reduction in the risk of
disease progression or death in CORRECT1^, 2

HR: 0.49
(95% CI, 0.42-0.58) P<0.0001

51% reduction in the risk of
disease progression or death in CORRECT1,2

HR: 0.49
(95% CI, 0.42-0.58) P<0.0001

Disease control rate (DCR)

Disease control with 41% of patients treated with STIVARGA vs 15% with placebo2

DCR included a 41% stable disease rate and a 1% partial response rate in the STIVARGA arm (n=207/505) vs a 15% stable disease rate and a 0.4% partial response rate in the placebo arm (n=38/255)2
- Disease control is defined as proportion of patients with a best response of complete or partial response or stable disease; assessment of stable disease had to be made at least 6 weeks after randomization

CORRECT trial study design

Multicenter, randomized, double-blind, placebo-controlled, phase 3 trial2

A large, international, phase 3, double-blind, randomized trial involving 760 patients1^,2

CORRECT trial design diagram. Patients intolerant to standard therapies were randomly (2:1 ratio) treated with Stivarga (regorafenib) or placebo + BSC. Treatment continued until disease progression of unacceptable toxicity. Tumor assessed every 8 weeks by RECIST 1.1 criteria.

Study arms abbreviated as STIVARGA and placebo throughout this website
Stratification: Prior treatment with anti-VEGF drugs, time from diagnosis of mCRC, and geographical region2
Treatment continued until disease progression or unacceptable toxicity2
Tumors were assessed every 8 weeks by RECIST 1.1 criteria2
No crossover between treatment groups was allowed2

CORRECT trial patient population

Most demographics and disease characteristics were similar between arms in the CORRECT trial2

Baseline characteristics2

	STIVARGA (n=505)	Placebo (n=255)
Median age, y	61	61
Sex
Male	62%	60%
Female	38%	40%
Disease site
Colon	64%	68%
Rectum	30%	27%
Both	6%	5%
*Historical KRAS* status**
Mutated	54%	62%
Race
White	78%	79%
Black or African American	1%	3%
Asian	15%	14%
Other or not specified	6%	4%
ECOG performance status
ECOG PS 0	52%	57%
ECOG PS 1	48%	43%

Guidelines list STIVARGA as a potential treatment option in third line3,4

STAR-T Data: Complementary Results

Exploring the use of regorafenib in real-world^¶ patients who no longer benefit from IV chemotherapy^1,6

^¶RWE complements data from randomized clinical trials. It is important to understand both the randomized clinical trial results and the limitations of retrospective real world studies. Observational retrospective analyses are not intended for direct comparison with clinical trials.

STUDY DESIGN

Data source6

STAR-T was a retrospective cohort study (N=818)
Data source was the Flatiron Health electronic heath record database
The Flatiron dataset was derived from mCRC patient charts from more than 280 cancer clinics across the US

Graphic indicating inclusion criteria graphic

Inclusion criteria6

Patients were aged ≥18 years at the time of mCRC diagnosis
Patients received sequential treatment with regorafenib followed by trifluridine/tipiracil ± bevacizumab (R-T) or vice versa (T-R), from January 2015 to November 2022
Patients were divided into 2 cohorts: R-T (n=393) or T-R (n=425) and stratified by line of treatment (third or fourth line)

Graph indicating improvement

Objectives6

Primary objective: to describe demographic, clinical characteristics, and biomarkers of patients who received sequential treatment with R-T or T-R
Secondary objectives: to describe subsequent therapies, frequency and incidence of neutropenia and myelosuppression-related medical interventions, duration of sequential treatment, and OS of patients treated with R-T or T-R

STUDY LIMITATIONS6

This was a retrospective analysis based on health records, which may have missing or erroneous data entry
Given the nature of the information, progression was not centrally assessed
Dosing information was not collected as part of the study

Secondary objectives of STAR-T study in patients with mCRC treated sequentially with regorafenib

Secondary objectives: OS and subsequent therapies6

STAR-T FINDINGS2,6

Approximately 1/3 of patients in the R-T arm received further treatment

Safety Findings6

39% of patients who started sequential therapy with regorafenib reported neutropenia
14% of patients who started sequential therapy with regorafenib used G-CSF

Watch Video: STIVARGA in mCRC

STIVARGA in GIST

Indications

STIVARGA is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.

STIVARGA is indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.

STIVARGA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Important Safety Information

WARNING: HEPATOTOXICITY

Severe and sometimes fatal hepatotoxicity has occurred in clinical trials.
Monitor hepatic function prior to and during treatment.
Interrupt and then reduce or discontinue STIVARGA for hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis, depending upon severity and persistence.

Hepatotoxicity: Severe drug-induced liver injury with fatal outcome occurred in STIVARGA-treated patients across all clinical trials. In most cases, liver dysfunction occurred within the first 2 months of therapy and was characterized by a hepatocellular pattern of injury. In metastatic colorectal cancer (mCRC), fatal hepatic failure occurred in 1.6% of patients in the STIVARGA arm and in 0.4% of patients in the placebo arm. In gastrointestinal stromal tumor (GIST), fatal hepatic failure occurred in 0.8% of patients in the STIVARGA arm. In hepatocellular carcinoma (HCC), there was no increase in the incidence of fatal hepatic failure as compared to placebo.

Liver Function Monitoring: Obtain liver function tests (ALT, AST, and bilirubin) before initiation of STIVARGA and monitor at least every 2 weeks during the first 2 months of treatment. Thereafter, monitor monthly or more frequently as clinically indicated. Monitor liver function tests weekly in patients experiencing elevated liver function tests until improvement to less than 3 times the upper limit of normal (ULN) or baseline values. Temporarily hold and then reduce or permanently discontinue STIVARGA, depending on the severity and persistence of hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis.

Infections: STIVARGA caused an increased risk of infections. The overall incidence of infection (Grades 1-5) was higher (32% vs 17%) in 1142 STIVARGA-treated patients as compared to the control arm in randomized placebo-controlled trials. The incidence of grade 3 or greater infections in STIVARGA treated patients was 9%. The most common infections were urinary tract infections (5.7%), nasopharyngitis (4.0%), mucocutaneous and systemic fungal infections (3.3%) and pneumonia (2.6%). Fatal outcomes caused by infection occurred more often in patients treated with STIVARGA (1.0%) as compared to patients receiving placebo (0.3%); the most common fatal infections were respiratory (0.6% vs 0.2%). Withhold STIVARGA for Grade 3 or 4 infections, or worsening infection of any grade. Resume STIVARGA at the same dose following resolution of infection.

Hemorrhage: STIVARGA caused an increased incidence of hemorrhage. The overall incidence (Grades 1-5) was 18.2% in 1142 patients treated with STIVARGA vs 9.5% with placebo in randomized, placebo-controlled trials. The incidence of grade 3 or greater hemorrhage in patients treated with STIVARGA was 3.0%. The incidence of fatal hemorrhagic events was 0.7%, involving the central nervous system or the respiratory, gastrointestinal, or genitourinary tracts. Permanently discontinue STIVARGA in patients with severe or life-threatening hemorrhage and monitor INR levels more frequently in patients receiving warfarin.

Gastrointestinal Perforation or Fistula: Gastrointestinal perforation occurred in 0.6% of 4518 patients treated with STIVARGA across all clinical trials of STIVARGA administered as a single agent; this included eight fatal events. Gastrointestinal fistula occurred in 0.8% of patients treated with STIVARGA and in 0.2% of patients in the placebo arm across randomized, placebo-controlled trials. Permanently discontinue STIVARGA in patients who develop gastrointestinal perforation or fistula.

Dermatological Toxicity: In randomized, placebo-controlled trials, adverse skin reactions occurred in 71.9% of patients with STIVARGA arm and 25.5% of patients in the placebo arm including hand-foot skin reaction (HFSR) also known as palmar-plantar erythrodysesthesia syndrome (PPES) and severe rash, requiring dose modification. In the randomized, placebo-controlled trials, the overall incidence of HFSR was higher in 1142 STIVARGA-treated patients (53% vs 8%) than in the placebo-treated patients. Most cases of HFSR in STIVARGA-treated patients appeared during the first cycle of treatment. The incidences of Grade 3 HFSR (16% vs <1%), Grade 3 rash (3% vs <1%), serious adverse reactions of erythema multiforme (<0.1% vs 0%), and Stevens-Johnson syndrome (<0.1% vs 0%) were higher in STIVARGA-treated patients. Across all trials, a higher incidence of HFSR was observed in Asian patients treated with STIVARGA (all grades: 72%; Grade 3: 18%). Toxic epidermal necrolysis occurred in 0.02% of 4518 STIVARGA-treated patients across all clinical trials of STIVARGA administered as a single agent. Withhold STIVARGA, reduce the dose, or permanently discontinue depending on the severity and persistence of dermatologic toxicity.

Hypertension: Hypertensive crisis occurred in 0.2% in STIVARGA-treated patients and in none of the patients in placebo arm across all randomized, placebo-controlled trials. STIVARGA caused an increased incidence of hypertension (30% vs 8% in mCRC, 59% vs 27% in GIST, and 31% vs 6% in HCC). The onset of hypertension occurred during the first cycle of treatment in most patients who developed hypertension (67% in randomized, placebo controlled trials). Do not initiate STIVARGA until blood pressure is adequately controlled. Monitor blood pressure weekly for the first 6 weeks of treatment and then every cycle, or more frequently, as clinically indicated. Temporarily or permanently withhold STIVARGA for severe or uncontrolled hypertension.

Cardiac Ischemia and Infarction: STIVARGA increased the incidence of myocardial ischemia and infarction (0.9% with STIVARGA vs 0.2% with placebo) in randomized placebo-controlled trials. Withhold STIVARGA in patients who develop new or acute cardiac ischemia or infarction, and resume only after resolution of acute cardiac ischemic events if the potential benefits outweigh the risks of further cardiac ischemia.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Reversible posterior leukoencephalopathy syndrome (RPLS), a syndrome of subcortical vasogenic edema diagnosed by characteristics finding on MRI, occurred in one of 4800 STIVARGA-treated patients across all clinical trials. Perform an evaluation for RPLS in any patient presenting with seizures, severe headache, visual disturbances, confusion, or altered mental function. Discontinue STIVARGA in patients who develop RPLS.

Wound Healing Complications: Impaired wound healing complications can occur in patients who receive drugs that inhibit the VEGF signaling pathway. Therefore, STIVARGA has the potential to adversely affect wound healing. Withhold STIVARGA for at least 2 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of STIVARGA after resolution of wound healing complications has not been established.

Embryo-Fetal Toxicity: STIVARGA can cause fetal harm when administered to a pregnant woman. There are no available data on STIVARGA use in pregnant women. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with STIVARGA and for 2 months after the final dose.

Nursing Mothers: Because of the potential for serious adverse reactions in breastfed infants from STIVARGA, do not breastfeed during treatment with STIVARGA and for 2 weeks after the final dose.

Most Frequently Observed Adverse Drug Reactions in mCRC (≥30%): The most frequently observed adverse drug reactions (≥30%) in STIVARGA-treated patients vs placebo-treated patients in mCRC, respectively, were: asthenia/fatigue (64% vs 46%), pain (59% vs 48%), decreased appetite and food intake (47% vs 28%), HFSR/PPE (45% vs 7%), diarrhea (43% vs 17%), mucositis (33% vs 5%), weight loss (32% vs 10%), infection (31% vs 17%), hypertension (30% vs 8%), and dysphonia (30% vs 6%).

Most Frequently Observed Adverse Drug Reactions in GIST (≥30%): The most frequently observed adverse drug reactions (≥30%) in STIVARGA-treated patients vs placebo-treated patients in GIST, respectively, were: HFSR/PPE (67% vs 12%), pain (60% vs 55%), hypertension (59% vs 27%), asthenia/fatigue (52% vs 39%), diarrhea (47% vs 9%), mucositis (40% vs 8%), dysphonia (39% vs 9%), infection (32% vs 5%), decreased appetite and food intake (31% vs 21%), and rash (30% vs 3%).

Most Frequently Observed Adverse Drug Reactions in HCC (≥30%): The most frequently observed adverse drug reactions (≥30%) in STIVARGA-treated patients vs placebo-treated patients in HCC, respectively, were: pain (55% vs 44%), HFSR/PPE (51% vs 7%), asthenia/fatigue (42% vs 33%), diarrhea (41% vs 15%), hypertension (31% vs 6%), infection (31% vs 18%), decreased appetite and food intake (31% vs 15%).

For important risk and use information, please see the full Prescribing Information including the Boxed Warning.

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

G-CFS=granulocyte colony-stimulating factor; mCRC=metastatic colorectal cancer; OS=overall survival; RWE=real-world evidence.

References:

STIVARGA. Prescribing information. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; December 2020. Return to content
Grothey A, Van Cutsem E, Sobrero A, et al; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-312. Return to content
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Colon Cancer. V.2.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed May 24, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. Return to content
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Rectal Cancer V.2.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed May 24, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. Return to content
Grothey A, Van Cutsem E, Sobrero A, et al; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial [supplement published online November 22, 2012]. Lancet. http://dx.doi.org/10.1016/S0140-6736(12)61900-X. Return to content
Bekaii-Saab TS, Ahn DH, Yuan C, et al. Sequential treatment with regorafenib and trifluridine/tipiracil ± bevacizumab in refractory metastatic colorectal cancer in community clinical practice in the USA. Poster presented at: 2023 European Society for Medical Oncology (ESMO) Congress; October 20-24, 2023; Madrid, Spain. Poster 616P. Return to content

This site is intended for US audiences only.

Last updated on July 2024

Choose STIVARGA^® (regorafenib) for your patients Post-IV chemo

Sequencing* regorafenib in mCRC prolongs survival1-4

*NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) recommend regorafenib as a potential treatment option for patients with previously treated mCRC3,4